Caprock Group LLC Buys 68 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Caprock Group LLC boosted its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 6.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,105 shares of the medical instruments supplier’s stock after purchasing an additional 68 shares during the quarter. Caprock Group LLC’s holdings in West Pharmaceutical Services were worth $364,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in WST. Fidelis Capital Partners LLC bought a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $27,000. Crewe Advisors LLC boosted its holdings in West Pharmaceutical Services by 322.7% in the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 71 shares during the period. Quarry LP grew its position in shares of West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. bought a new position in shares of West Pharmaceutical Services in the first quarter worth $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter worth $40,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

NYSE:WST opened at $297.48 on Friday. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70. The stock has a fifty day moving average of $305.71 and a 200 day moving average of $339.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. The firm has a market capitalization of $21.67 billion, a price-to-earnings ratio of 39.25, a P/E/G ratio of 10.60 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business’s revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.11 EPS. On average, research analysts expect that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now directly owns 1,478 shares of the company’s stock, valued at approximately $443,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.